{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:31:16Z","timestamp":1792409476660,"version":"4.4.0"},"reference-count":51,"publisher":"The Pediatric Pharmacy Association","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"abstract":"<jats:p>Tourette syndrome is a hyperkinetic movement disorder that presents before age 18 years and involves motor and phonic tics that may present with a wide range of severity. The severity and presentation of tics in an individual may fluctuate over time. Tourette syndrome may affect social relationships and school attendance, and may result in depression. Comorbidities are common, with attention-deficit\/hyperactivity disorder and obsessive-compulsive disorder being most common. The literature supporting optimal treatment is limited but provides a framework for clinical decision-making. The focus of this review is to discuss the symptoms and possible causes of Tourette syndrome and current non-pharmacologic and pharmacologic treatment options, to help practitioners optimize care for pediatric patients with this disease.<\/jats:p>","DOI":"10.5863\/1551-6776-25.5.401","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T21:54:12Z","timestamp":1593554052000},"page":"401-412","source":"Crossref","is-referenced-by-count":20,"title":["A Review of the Current Treatment of Tourette Syndrome"],"prefix":"10.5863","volume":"25","author":[{"given":"Mary F.","family":"Seideman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis A.","family":"Seideman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"key":"i1551-6776-25-5-401-b1","article-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013","unstructured":"American Psychiatric Association\n          . Diagnostic and Statistical Manual of Mental Disorders. 5th ed.Arlington, VA: American Psychiatric Association; 2013."},{"issue":"4","key":"i1551-6776-25-5-401-b2","series-title":"J Dev Behav Pediatr","first-page":"335","article-title":"Impact of Tourette syndrome on school measures in a nationally representative sample","volume":"39","year":"2018","unstructured":"Claussen\n              AH\n            , BitskoRH, HolbrookJR, \n          et al. Impact of Tourette syndrome on school measures in a nationally representative sample. J Dev Behav Pediatr. 2018;39(4):335\u2013342."},{"key":"i1551-6776-25-5-401-b3","series-title":"Adv Neurol","first-page":"240","article-title":"Public health significance of tic disorders in children and adolescents","volume":"96","year":"2005","unstructured":"Scahill\n              L\n            , SukhodolskyDG, WilliamsSK, LeckmanJ.\n          Public health significance of tic disorders in children and adolescents. Adv Neurol. 2005;96:240\u2013248."},{"key":"i1551-6776-25-5-401-b4","series-title":"J Psychopathol Behav Assess","first-page":"211","article-title":"Peer victimization in youth with Tourette's syndrome and chronic tic disorder: relations with tic severity and internalizing symptoms","volume":"29","year":"2007","unstructured":"Storch\n              EA\n            , MurphyTK, ChaseRM, KeeleyM, \n          et al. Peer victimization in youth with Tourette's syndrome and chronic tic disorder: relations with tic severity and internalizing symptoms. J Psychopathol Behav Assess. 2007;29:211\u2013219."},{"issue":"2","key":"i1551-6776-25-5-401-b5","series-title":"J Child Neurol","first-page":"171","article-title":"The presence of attention-deficit hyperactivity disorder (ADHD) and obsessive compulsive disorder worsen psychosocial and educational problems in Tourette syndrome","volume":"25","year":"2010","unstructured":"Debes\n              N\n            , HjalgrimH, SkovL.\n          The presence of attention-deficit hyperactivity disorder (ADHD) and obsessive compulsive disorder worsen psychosocial and educational problems in Tourette syndrome. J Child Neurol. 2010;25(2):171\u2013181."},{"issue":"1","key":"i1551-6776-25-5-401-b6","series-title":"Child Psychiatry Hum Dev","first-page":"124","article-title":"Peer victimization in youth with Tourette syndrome and other chronic tic disorders","volume":"43","year":"2012","unstructured":"Zinner\n              SH\n            , ConeleaCA, Glew, GM, \n          et al. Peer victimization in youth with Tourette syndrome and other chronic tic disorders. Child Psychiatry Hum Dev. 2012; 43(1):124\u2013136."},{"key":"i1551-6776-25-5-401-b7","series-title":"J Neurol Sci","first-page":"128","article-title":"Depression in Tourette syndrome: a controlled and comparison study","volume":"364","year":"2016","unstructured":"Piedad\n              JCP\n            , CavannaAE.\n          Depression in Tourette syndrome: a controlled and comparison study. J Neurol Sci. 2016;364:128\u2013132."},{"issue":"4","key":"i1551-6776-25-5-401-b8","series-title":"JAMA Psychiatry","first-page":"325","article-title":"Lifetime prevalence, age of risk, and etiology of comorbid psychiatric disorders in Tourette syndrome","volume":"72","year":"2015","unstructured":"Hirschtritt\n              M\n            , LeePC, PaulsDL, \n          et al. Lifetime prevalence, age of risk, and etiology of comorbid psychiatric disorders in Tourette syndrome. JAMA Psychiatry. 2015;72(4):325\u2013333."},{"issue":"3","key":"i1551-6776-25-5-401-b9","series-title":"Am J Psychiatry","first-page":"217","article-title":"Interrogating the genetic determinants of Tourette's syndrome and other tic disorders through genome-wide association studies","volume":"176","year":"2019","unstructured":"Dongmei\n              Y\n            , JaeHoonS, FotisT, \n          et al. Interrogating the genetic determinants of Tourette's syndrome and other tic disorders through genome-wide association studies. Am J Psychiatry. 2019;176(3):217\u2013227."},{"issue":"6","key":"i1551-6776-25-5-401-b10","series-title":"Neuropsychopharmacology","first-page":"1239","article-title":"Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET","volume":"33","year":"2008","unstructured":"Wong\n              DF\n            , BrasicJR, SingerHS, \n          et al\n          Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology. 2008;33(6):1239\u20131251."},{"issue":"2","key":"i1551-6776-25-5-401-b11","series-title":"Neurosci Lett","first-page":"120","article-title":"Serotonin transporter binding is increased in Tourette syndrome","volume":"385","year":"2005","unstructured":"Muller-Vahl\n              KR\n            , SzejkoN, WilkeF, \n          et al. Serotonin transporter binding is increased in Tourette syndrome. Neurosci Lett. 2005;385(2):120\u2013125."},{"issue":"1","key":"i1551-6776-25-5-401-b12","series-title":"Transl Psychiatry","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41398-018-0202-y","article-title":"Striatal dopaminergic alterations in Tourette's syndrome: a meta-analysis based on 16 PET and SPECT neuroimaging studies","volume":"8","year":"2018","unstructured":"Hienert\n              M\n            , GryglewskiG, StamenkovicM, \n          et al. Striatal dopaminergic alterations in Tourette's syndrome: a meta-analysis based on 16 PET and SPECT neuroimaging studies. Transl Psychiatry. 2018;8(1):143. doi:10.1038\/s41398-018-0202-y"},{"issue":"12","key":"i1551-6776-25-5-401-b13","series-title":"Am J Psychiatry","first-page":"1326","article-title":"The neural circuits that generate tics in Gilles de la Tourette syndrome","volume":"186","year":"2011","unstructured":"Wang\n              Z\n            , MiaiaTV, MarshR, \n          et al. The neural circuits that generate tics in Gilles de la Tourette syndrome. Am J Psychiatry. 2011;186(12):1326\u20131337."},{"issue":"1","key":"i1551-6776-25-5-401-b14","series-title":"Am J Psychiatry","first-page":"98","article-title":"Premonitory urges in Tourette's syndrome","volume":"150","year":"1993","unstructured":"Leckman\n              JF\n            , WalkerDE, CohenDJ.\n          Premonitory urges in Tourette's syndrome. Am J Psychiatry. 1993;150(1):98\u2013102."},{"issue":"5","key":"i1551-6776-25-5-401-b15","series-title":"J Dev Behav Pediatr","first-page":"317","article-title":"A national profile of Tourette syndrome, 2011\u20132012","volume":"35","year":"2014","unstructured":"Bitsko\n              RH\n            , HolbrookJR, VisserSN, \n          et al. A national profile of Tourette syndrome, 2011\u20132012. J Dev Behav Pediatr. 2014;35(5):317\u2013322."},{"issue":"21","key":"i1551-6776-25-5-401-b16","series-title":"MMWR Morb Mortal Wkly Rep.","first-page":"581","article-title":"Prevalence of diagnoses Tourette syndrome in persons aged 6\u201317 years-United States, 2007","volume":"58","year":"2007","unstructured":"Centers for Disease Control and Prevention (CDC)\n          . Prevalence of diagnoses Tourette syndrome in persons aged 6\u201317 years-United States, 2007. MMWR Morb Mortal Wkly Rep.2007;58(21):581\u2013585. https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5821a1.htm. Accessed May 20, 2019."},{"key":"i1551-6776-25-5-401-b17","series-title":"Haloperidol [package insert]","year":"2016","unstructured":"Haloperidol [package insert]. Greenville, SC; Pai Pharmacuetical Associates, Inc; 2016."},{"key":"i1551-6776-25-5-401-b18","series-title":"ORAP [package insert]","year":"2008","unstructured":"ORAP [package insert]. Sellersville, PA: Teva Pharmacueticals USA; 2008."},{"key":"i1551-6776-25-5-401-b19","series-title":"Abilify [package insert]","year":"2019","unstructured":"Abilify [package insert]. Tokyo, Japan: Otsuka Pharmaceutical Co, Ltd; 2019."},{"issue":"19","key":"i1551-6776-25-5-401-b20","series-title":"Neurology","first-page":"896","article-title":"Practice guidelines recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders","volume":"92","year":"2019","unstructured":"Pringsheim\n              T\n            , OkunMS, Muller-VahlK, \n          et al. Practice guidelines recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92(19):896\u2013906."},{"key":"i1551-6776-25-5-401-b21","series-title":"Clonidine Hydrochloride [package insert]","year":"2015","unstructured":"Clonidine Hydrochloride [package insert]. Rockford, IL: Mylan Institutional Inc; 2015."},{"key":"i1551-6776-25-5-401-b22","series-title":"Front Neurol","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fneur.2017.00032","article-title":"The efficacy and tolerability of the clonidine transdermal patch in the treatment of children with tic disorders: a prospective, open, single-group, self-controlled Study","volume":"8","year":"2017","unstructured":"Song\n              PP\n            , JiangL, LiXJ, \n          et al. The efficacy and tolerability of the clonidine transdermal patch in the treatment of children with tic disorders: a prospective, open, single-group, self-controlled Study. Front Neurol. 2017;8:32. doi:10.3389\/fneur.2017.00032"},{"issue":"4","key":"i1551-6776-25-5-401-b23","series-title":"Neurology","first-page":"527","article-title":"Treatment of ADHD in children with tics a randomized controlled trial","volume":"58","year":"2002","unstructured":"The Tourette's Syndrome Study Group\n          . Treatment of ADHD in children with tics a randomized controlled trial. Neurology. 2002;58(4):527\u2013536."},{"issue":"9","key":"i1551-6776-25-5-401-b24","series-title":"Aust N Z J Psychiatry","first-page":"807","article-title":"Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders","volume":"42","year":"2008","unstructured":"Du\n              YS\n            , LiHF, VanceA, \n          et al. Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust N Z J Psychiatry. 2008;42(9):807\u2013813."},{"issue":"6","key":"i1551-6776-25-5-401-b25","series-title":"Curr Treat Options Neurol","first-page":"465","article-title":"New treatments for tic disorders","volume":"8","year":"2006","unstructured":"Qasaymeh\n              MM\n            , MinkJW.\n          New treatments for tic disorders. Curr Treat Options Neurol. 2006;8(6):465\u2013473."},{"issue":"7","key":"i1551-6776-25-5-401-b26","series-title":"Am J Psychiatry","first-page":"1067","article-title":"A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder","volume":"158","year":"2001","unstructured":"Scahill\n              L\n            , ChappellPB, KimYS, \n          et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158(7):1067\u20131074."},{"key":"i1551-6776-25-5-401-b27","series-title":"Tenex [package insert]","year":"2013","unstructured":"Tenex [package insert]. Bridgewater, NJ: Promius Pharma; 2013."},{"issue":"6","key":"i1551-6776-25-5-401-b28","series-title":"Clin Neuropharmacol","first-page":"325","article-title":"Neuro-psychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study","volume":"25","year":"2002","unstructured":"Cummings\n              DD\n            , SingerHS, KriegerM, \n          et al. Neuro-psychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study. Clin Neuropharmacol. 2002;25(6):325\u2013332."},{"issue":"9","key":"i1551-6776-25-5-401-b29","series-title":"J Child Adolesc Psychopharmacol","first-page":"762","article-title":"Extended-release guanfacine does not show a large effect on tic severity in children with chronic tic disorders","volume":"27","year":"2017","unstructured":"Murphy\n              TK\n            , FernandezTV, CoffeyBJ, \n          et al. Extended-release guanfacine does not show a large effect on tic severity in children with chronic tic disorders. J Child Adolesc Psychopharmacol. 2017;27(9):762\u2013770."},{"issue":"2","key":"i1551-6776-25-5-401-b30","series-title":"Cochrane Database Syst Rev","doi-asserted-by":"publisher","first-page":"CD006996","DOI":"10.1002\/14651858.CD006996. pub2","article-title":"Pimozide for tics in Tourette's syndrome","year":"2009","unstructured":"Pringsheim\n              T\n            , MarrasC.\n          Pimozide for tics in Tourette's syndrome. Cochrane Database Syst Rev. 2009;(2):CD006996. doi:10.1002\/14651858.CD006996. pub2"},{"issue":"7","key":"i1551-6776-25-5-401-b31","series-title":"Neurology","first-page":"1130","article-title":"A placebo-controlled trial of risperidone in Tourette syndrome","volume":"60","year":"2003","unstructured":"Scahill\n              L\n            , LeckmanJF, SchultzRT, \n          et al. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60(7):1130\u20131135."},{"issue":"4","key":"i1551-6776-25-5-401-b32","series-title":"Eur Child Adolesc Psychiatry","first-page":"173","article-title":"European clinical guidelines for Tourette syndrome and other tic disorders, part II: pharmacological treatment","volume":"20","year":"2011","unstructured":"Roessner\n              V\n            , PlessenKJ, RothenbergerA, \n          et al. European clinical guidelines for Tourette syndrome and other tic disorders, part II: pharmacological treatment. Eur Child Adolesc Psychiatry.2011;20(4):173\u2013196."},{"issue":"8","key":"i1551-6776-25-5-401-b33","series-title":"Arch Gen Psychiatry","first-page":"722","article-title":"Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette's syndrome","volume":"46","year":"1989","unstructured":"Shapiro\n              E\n            , ShapiroAK, FulopG, \n          et al. Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry. 1989;46(8):722\u2013730."},{"issue":"3","key":"i1551-6776-25-5-401-b34","series-title":"Eur Child Adolesc Psychiatry","first-page":"127","article-title":"Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders","volume":"20","year":"2011","unstructured":"Yoo\n              HK\n            , LeeJS, PaikKW, \n          et al. Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders. Eur Child Adolesc Psychiatry. 2011;20(3):127\u2013135."},{"issue":"6","key":"i1551-6776-25-5-401-b35","series-title":"Pediatr Neurol","first-page":"419","article-title":"Metabolic effects of aripiprazole and pimozide in children with Tourette syndrome","volume":"47","year":"2012","unstructured":"Rizzo\n              R\n            , EddyCM, CaliP, \n          et al. Metabolic effects of aripiprazole and pimozide in children with Tourette syndrome. Pediatr Neurol. 2012;47(6):419\u2013422."},{"issue":"9","key":"i1551-6776-25-5-401-b36","series-title":"J Child Adolesc Psychopharmacol","first-page":"771","article-title":"randomized, double-blind, placebo controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette's disorder in children and adolescents","volume":"27","year":"2017","unstructured":"Sallee\n              F\n            , KohegyiE, ZhaoJ, \n          et al. randomized, double-blind, placebo controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette's disorder in children and adolescents. J Child Adolesc Psychopharmacol. 2017; 27(9):771\u2013781."},{"issue":"8","key":"i1551-6776-25-5-401-b37","series-title":"J Clin Psychiatry","first-page":"e772","article-title":"A multicenter, randomized, double-blind placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder","volume":"74","year":"2013","unstructured":"Yoo\n              HK\n            , JoungYS, LeeJS, \n          et al. A multicenter, randomized, double-blind placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder. J Clin Psychiatry. 2013;74(8):e772\u2013e780."},{"issue":"1","key":"i1551-6776-25-5-401-b38","series-title":"J Clin Psychopharmacol","first-page":"31","article-title":"Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial","volume":"22","year":"2002","unstructured":"Dion\n              Y\n            , AnnableL, StatD, \n          et al. Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2002;22(1):31\u201339."},{"issue":"3","key":"i1551-6776-25-5-401-b39","series-title":"J Am Acad Child Adolesc Psychiatry","first-page":"330","article-title":"Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome","volume":"41","year":"2002","unstructured":"Gaffney\n              GR\n            , PerryPJ, LundBC, \n          et al. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry. 2002;41(3):330\u2013336."},{"key":"i1551-6776-25-5-401-b40","series-title":"BOTOX [package insert]","year":"2019","unstructured":"BOTOX [package insert]. Madison, NJ: Allergan USA; 2019."},{"issue":"1","key":"i1551-6776-25-5-401-b41","series-title":"Cochrane Database Syst Rev","doi-asserted-by":"publisher","first-page":"CD012285","DOI":"10.1002\/14651858.CD012285.pub2","article-title":"Botulinum toxin for motor and phonic tics in Tourette's syndrome","year":"2018","unstructured":"Pandey\n              S\n            , SrivanitchapoomP, KirubakaranR, BermanB.\n          Botulinum toxin for motor and phonic tics in Tourette's syndrome. Cochrane Database Syst Rev. 2018;(1):CD012285. doi:10.1002\/14651858.CD012285.pub2"},{"issue":"5","key":"i1551-6776-25-5-401-b42","series-title":"Neurology","first-page":"605","article-title":"Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial","volume":"56","year":"2001","unstructured":"Marras\n              C\n            , AndrewsD, SimeE, LangAE.\n          Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology. 2001;56(5):605\u2013610."},{"issue":"4","key":"i1551-6776-25-5-401-b43","series-title":"Cochrane Database Syst Rev","doi-asserted-by":"publisher","first-page":"CD00656","DOI":"10.1002\/14651858.CD006565. pub2","article-title":"Cannabinoids for Tourette's syndrome","year":"2009","unstructured":"Curtis\n              A\n            , ClarkeCE, RickardsHE.\n          Cannabinoids for Tourette's syndrome. Cochrane Database Syst Rev. 2009;(4):CD00656. doi:10.1002\/14651858.CD006565. pub2"},{"issue":"1","key":"i1551-6776-25-5-401-b44","series-title":"Behav Neurol","first-page":"119","article-title":"Treatment of Tourette syndrome with cannabinoids","volume":"27","year":"2013","unstructured":"Muller-Vahl\n              KR.\n            \n          \n          Treatment of Tourette syndrome with cannabinoids. Behav Neurol. 2013;27(1):119\u2013124."},{"issue":"1","key":"i1551-6776-25-5-401-b45","series-title":"J Neurol Neurosurg Psychiatry","first-page":"70","article-title":"A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome","volume":"81","year":"2010","unstructured":"Jankovic\n              J\n            , Jimenez-ShahedJ, BrownLW.\n          A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010;81(1):70\u201373."},{"issue":"8","key":"i1551-6776-25-5-401-b46","series-title":"Lancet Neurol","first-page":"610","article-title":"Anterior pallidal deep brain stimulation for Tourette's syndrome: a randomised, double-blind, controlled trial","volume":"16","year":"2017","unstructured":"Welter\n              ML\n            , HouetoJL, ThoboisS, \n          et al. Anterior pallidal deep brain stimulation for Tourette's syndrome: a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16(8):610\u2013619."},{"issue":"3","key":"i1551-6776-25-5-401-b47","series-title":"JAMA Neurol","first-page":"353","article-title":"Efficacy and safety of deep brain stimulation in Tourette syndrome: the international Tourette syndrome deep bran stimulation public database and registry","volume":"75","year":"2018","unstructured":"Martinez-Ramirez\n              D\n            , Jiminez-ShahedJ, LeckmanJF, \n          et al. Efficacy and safety of deep brain stimulation in Tourette syndrome: the international Tourette syndrome deep bran stimulation public database and registry. JAMA Neurol. 2018;75(3):353\u2013359."},{"issue":"2","key":"i1551-6776-25-5-401-b48","series-title":"Brain Stimul","first-page":"296","article-title":"Deep brain stimulation for Tourette-syndrome: a systematic review and meta-analysis","volume":"9","year":"2016","unstructured":"Baldermann\n              JC\n            , SchullerT, HuysD, \n          et al. Deep brain stimulation for Tourette-syndrome: a systematic review and meta-analysis. Brain Stimul. 2016;9(2):296\u2013304."},{"issue":"10","key":"i1551-6776-25-5-401-b49","series-title":"J Neurol Neurosurg Psychiatry","first-page":"1078","article-title":"Image-based analysis and long-term clinical outcomes of deep brain stimulation for Tourette syndrome: a multisite study","volume":"90","year":"2019","unstructured":"Johnson\n              KA\n            , FletcherPT, ServelloD, BonaA, \n          et al. Image-based analysis and long-term clinical outcomes of deep brain stimulation for Tourette syndrome: a multisite study. J Neurol Neurosurg Psychiatry. 2019;90(10):1078\u20131090."},{"issue":"19","key":"i1551-6776-25-5-401-b50","series-title":"JAMA","first-page":"1929","article-title":"Behavior therapy for children with Tourette disorder: a randomized controlled trial","volume":"303","year":"2010","unstructured":"Piacentini\n              J\n            , WoodsDW, ScahillL.\n          Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA. 2010; 303(19):1929\u20131937."},{"issue":"8","key":"i1551-6776-25-5-401-b51","series-title":"Arch Gen Psychiatry","first-page":"795","article-title":"Randomized trial of behavior therapy for adults with Tourette's disorder","volume":"69","year":"2012","unstructured":"Wilhelm\n              S\n            , PetersonAL, PiacentiniJ, \n          et al. Randomized trial of behavior therapy for adults with Tourette's disorder. Arch Gen Psychiatry. 2012;69(8):795\u2013803."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/25\/5\/article-p401.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/25\/5\/401\/2561363\/1551-6776-25_5_401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/25\/5\/article-p401.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/25\/5\/article-p401.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:39:18Z","timestamp":1747355958000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/25\/5\/article-p401.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":51,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-25.5.401","relation":{},"ISSN":["1551-6776"],"issn-type":[{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}